This trial is studying a combination of drugs as a potential treatment for newly diagnosed malignant glioma. The drugs being studied are veliparib, radiation therapy, and temozolomide.
1 Primary · 2 Secondary · Reporting Duration: Up to 5.5 years
Experimental Treatment
115 Total Participants · 1 Treatment Group
Primary Treatment: Veliparib · No Placebo Group · Phase 2
Age 3 - 25 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 50.0% |
North Carolina | 50.0% |
65+ | 50.0% |
18 - 65 | 50.0% |
Carolinas Medical Center/Levine Cancer Institute | 100.0% |
Did not meet criteria | 50.0% |
Met criteria | 50.0% |